What are the evidence‑based treatment options for adult alopecia, including male and female pattern hair loss and alopecia areata?

Evidence-Based Treatment of Adult Alopecia

For alopecia areata with severe disease (≥50% scalp hair loss), baricitinib is the first-line systemic treatment, demonstrating high-certainty evidence for both short-term and long-term hair regrowth ≥75% compared to placebo. 1

Alopecia Areata Management

Limited Patchy Disease (<25% scalp involvement)

Observation without treatment is a legitimate first-line approach for limited patchy alopecia areata of short duration (<1 year), as spontaneous remission occurs in up to 80% of these patients. 2

• Reassure patients that regrowth cannot be expected within 3 months of any individual patch developing 2
• Consider active treatment for cosmetically sensitive areas (eyebrows) or patient preference 2

Moderate Disease (25-50% scalp involvement)

Intralesional corticosteroids are the primary treatment modality:

• Use triamcinolone acetonide 5-10 mg/mL injected just beneath the dermis into the upper subcutis 2, 3
• Inject 0.05-0.1 mL per site, producing approximately 0.5 cm diameter of hair regrowth 2, 3
• Administer monthly injections; therapeutic effect persists approximately 9 months 2, 3
• In one study, 62% of patients with fewer than five patches <3 cm diameter achieved full regrowth 2
• Patient discomfort is the main limitation 2, 3

Alternative: Very potent topical corticosteroids

• Clobetasol propionate 0.05% foam applied to affected areas 2
• In one trial, 7 of 34 sites treated with clobetasol achieved ≥50% regrowth versus 1 of 34 placebo sites at 12 weeks 2
• Folliculitis is a frequent adverse effect requiring monitoring 2, 3
• Repeated use can cause skin atrophy 3

Severe Disease (≥50% scalp involvement, alopecia totalis, alopecia universalis)

Baricitinib (JAK1/JAK2 inhibitor) is the evidence-based first-line systemic treatment:

• Results in a 7.54-fold increase in short-term hair regrowth ≥75% compared to placebo (high-certainty evidence) 1
• Results in an 8.49-fold increase in long-term hair regrowth ≥75% compared to placebo (high-certainty evidence) 1
• FDA and EMA approved for severe alopecia areata in adults 4, 5
• Monitor for serious adverse events, though incidence remains low 1

Alternative JAK inhibitors:

• Ritlecitinib (JAK3/TEC inhibitor) approved for patients aged ≥12 years with severe disease 5
• Oral ruxolitinib versus oral tofacitinib showed uncertain comparative efficacy (very low-certainty evidence) 1

Off-label systemic options with limited evidence:

• Oral corticosteroids (betamethasone, prednisolone): very low to low-certainty evidence 1
• Cyclosporine, methotrexate, azathioprine: used off-label with limited supporting data 5
• Dupilumab: may result in little to no difference versus placebo (low-certainty evidence) 1

Contact immunotherapy (diphencyprone, squaric acid dibutyl ester):

• Very low-certainty evidence for efficacy versus placebo or minoxidil 1
• Historically used but evidence base remains weak 2

Prognosis Considerations

• Disease severity at presentation is the strongest predictor of long-term outcome 2
• Patients with <25% initial hair loss: 68% report being disease-free at long-term follow-up 2
• Patients with >50% initial hair loss: only 8% report being disease-free at long-term follow-up 2
• Full recovery from alopecia totalis/universalis is unusual (<10%) 2
• Prognosis in longstanding extensive alopecia is poor; wigs may be more appropriate than treatments unlikely to be effective 2

Androgenetic Alopecia (Male and Female Pattern Hair Loss)

Female Pattern Hair Loss (FPHL)

Topical minoxidil is the only first-line treatment with high-level evidence:

• Remains the first-choice treatment since the 1990s 6
• Approximately 40% of patients do not show improvement, requiring alternative approaches 6
• Minoxidil 1% and 2% versus placebo showed increased hair regrowth in alopecia areata trials (very low-certainty evidence), though this data is less robust for androgenetic alopecia 1

Antiandrogens (off-label):

• Spironolactone is used for FPHL, particularly in women with hyperandrogenic features 7
• Evidence level remains limited compared to minoxidil 6

Emerging therapies:

• Regenerative medicine approaches, nanotechnology, and improved delivery systems show promise 7
• Hair follicle mesenchymal stem cells demonstrated effectiveness in advanced AGA, particularly for miniaturized follicles with hair shaft diameter <60 µm 8

Male Pattern Hair Loss

Finasteride is a standard systemic treatment:

• Well-established efficacy for male androgenetic alopecia 7
• Combined with topical minoxidil for enhanced outcomes 7

JAK inhibitors:

• Emerging as potential treatments for androgenetic alopecia 7
• Evidence base continues to develop 7

Key Clinical Pitfalls

• Avoid aggressive treatment in limited patchy alopecia areata with short duration: High spontaneous remission rates make observation appropriate 2
• Do not use intralesional corticosteroids for extensive scarring: Greatest benefit occurs in limited, actively inflamed areas 3
• Monitor for folliculitis and skin atrophy: Routine assessment during follow-up visits is essential when using potent topical corticosteroids 3
• Recognize treatment-resistant populations: Patients with longstanding extensive disease (alopecia totalis/universalis) are resistant to most treatments; wigs may be more appropriate 2
• Balance serious adverse event risk with baricitinib benefits: While serious adverse events are reported, the small incidence should be weighed against substantial hair regrowth benefits 1